Controversy. Dabigatran in the preventive treatment embolic stroke: For use as first-line drug;Controversia. dabigatrán en el tratamiento preventivo del ictus embólico: A favor de su utilización como fármaco de primera línea

Revista de Neurologia

Volumn 54, Issue 5, 2012, Pages 257-259

  Masjuán, Jaime ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DRUG DERIVATIVE; N ((2 (((4 (AMINOIMINOMETHYL)PHENYL)AMINO)METHYL) 1 METHYL 1H BENZIMIDAZOL 5 YL)CARBONYL) N 2 PYRIDINYL BETA ALANINE; N-((2-(((4-(AMINOIMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-BETA-ALANINE;

ARTICLE; EMBOLISM; STROKE; BRAIN EMBOLISM; CEREBROVASCULAR ACCIDENT; HUMAN;

ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; INTRACRANIAL EMBOLISM; STROKE;

EID: 84857856754     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5405.2012086     Document Type: Article

References (11)

1. Gil-Núñez A. Advances in the prevention of cerebral ischaemia due to atrial fibrillation. Neurología 2010; 25: 401-408.
2. Medi C, Hankey GJ, Freedman SB. Stroke risk and antithrombotic strategies in atrial fibrillation. Stroke 2010; 41: 2705-2713.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
4. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119 (Suppl): S194-S206.
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
7. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
8. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262.
9. Gladstone, DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009; 40: 235-240.
10. Fuentes B, Gállego J, Gil-Núñez A, Morales A, Purroy F, Roquer J, et al. Guías para el tratamiento preventivo del ictus isquémico y AIT (I). Actuación sobre los factores de riesgo y estilos de vida. Neurologia 2011; Sep 19. [Epub ahead of print].
11. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, et al; RE-LY Study Group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9: 1157-63.